Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

NEW YORK, Aug. 7 (Xinhua) -- U.S. stocks ended mixed on Thursday as markets reacted to a sweeping new round of tariffs imposed by U.S. President Donald Trump on a broad range of U.S. trade partners.